Ponatinib Hydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In December 2012, the US FDA approved ponatinib (also referred to as AP 24534) for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronicmyeloid leukemia (CML). Ponatinib is a pan-Bcr–Abl TKI that blocks both the native (IC
50=0.4 nM) and Bcr– Abl
T315I mutated kinases (IC
50=2.0 nM) in addition to othermutated kinases in CML patients. In the Ba/F3 cell proliferation assay, ponatinib inhibits ABL and the T315I Abl mutant with IC
50s of 1.2 and 8.8 nM, respectively. Ponatinib was identified by a structure-based drug design approach. Ponatinib binds to the kinase domain in a DFG-out conformation; the ethynyl moiety helps the inhibitor evade the mutant gatekeeper isoleucine residue at position 315. In addition to Abl and the T315I mutant of Abl, ponatinib inhibits VEGFR, PDGFR, FGFR, SRC, KIT, RET, TIE2, FLT3, and EPH receptors at concentrations ranging from0.1 to 20 nM.
Verwenden
Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. Potent FAK inhibitor. FGFR/VEGFR/Bcr-Abl inhibitor It is a COVID19-related research product.
Clinical Use
Ponatinib hydrochloride (Iclusig ®), previously known as AP24534, is a multi-targeted tyrosine kinase
inhibitor approved in the US as an oral treatment for resistant or intolerant chronic myeloid leukemia
(CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib
hydrochloride was designed for treatment of tumors containing the T351I mutation which are present in
some forms of CML and resistant to traditional therapies such as imatinib. Ponatinib
hydrochloride was developed by Ariad Pharmaceauticals, and operates by a similar mechanism of action
as other tyrosine kinase inhibitors, inhibiting the enzymatic activity of BCR-ABL, an abnormal tyrosine
kinase responsible for unregulated and excess white blood cell production by bone marrow. However, the ability of ponatinib hydrochloride to target isoforms of the BCR-ABL gene typically
leading to resistance in other known tyrosine kinase inhibitors provides an alternate form of therapy not
previously available.
Ponatinib Hydrochloride Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
